Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 February 2026 to Question 110592, whether his Department has made an estimate of the earliest date nerandomilist could become available to patients after NICE publishes its final guidance.

Subject to licensing, the National Institute for Health and Care Excellence (NICE) currently expects to publish final guidance on nerandomilast in September 2026. In formulating its recommendations, NICE's independent Appraisal Committee expects to hold its first meeting on 15 July. If the Appraisal Committee is able to recommend nerandomilast, NICE would aim to publish its final draft guidance within three weeks of the committee meeting.

If recommended in final NICE guidance, the National Health Service would be required to fund treatment within three months, although some medicines are provided sooner through support from the Innovative Medicines Fund.